Compare Medtronic PLC (MDT) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Nomura Holdings Inc — how do they compare? Medtronic PLC trades at $82.79 (market cap $106.61B), while Nomura Holdings Inc trades at $9.78 (market cap $27.46B). The key difference: Medtronic PLC is far larger — about 3.9× Nomura Holdings Inc's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | NMR | |
|---|---|---|
Market Cap | $106.61B | $27.46B |
Sector | Health | Financials |
52-Week High | $105.35 | $10.04 |
52-Week Low | $73.75 | $6.39 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Nomura Holdings (NMR) trades at $9.395, down 0.05% on the day, with a bullish technical signal from moving averages. The company reported record annual net income of $340.74 billion for 2025, with a net income margin of 20.49%, while revenue grew to $1.66 trillion. Recent news highlights strong wholesale revenue momentum and strategic acquisitions, including a U.S. fund management expansion. The stock shows a P/E of 12.78 and P/B of 1.2, indicating potential value relative to earnings.
The outlook for NMR is supported by earnings growth and strategic initiatives, but risks include volatile cash flows and rising debt levels. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism. Further upside depends on sustained profitability and successful integration of recent acquisitions amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
